Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
Powered By

Drug Combo Extends Survival in Extensive-Stage SCLC Trial

Written by Ted Samson
Posted on November 16, 2026

Adding the immunotherapy drug tarlatamab-dlle (Imdelltra) to durvalumab (Imfinzi) helped people with extensive-stage small cell lung cancer (SCLC) live a median of 8.4 months longer than those receiving durvalumab alone, according to a recent phase 3 study.

Extensive-stage SCLC has spread widely within the chest or to other parts of the body.

Read on to learn more details about the study and its findings.

🗳️ Would you consider joining a clinical trial for a new drug combination, if your doctor suggested it?
Yes
No
I’m not sure

What Does Maintenance Treatment Mean?

Maintenance treatment is given after initial treatment has helped control cancer. Its goal is to keep the cancer from worsening for as long as possible.

Tarlatamab is a type of immunotherapy called a bispecific T-cell engager. It works by bringing immune cells called T cells close to lung cancer cells, helping the immune system attack the cancer.

The U.S. Food and Drug Administration (FDA) has approved tarlatamab for adults with extensive-stage SCLC whose cancer worsened during or after platinum-based chemotherapy.

Durvalumab is another type of immunotherapy. It blocks a protein called PD-L1, helping the immune system recognize and attack cancer cells.

What Did the Study Find?

In the trial, researchers randomly assigned 282 people to receive tarlatamab plus durvalumab and 281 people to receive durvalumab alone. Everyone had extensive-stage SCLC that hadn’t worsened after initial treatment with durvalumab and chemotherapy.

The study measured overall survival and progression-free survival beginning when participants started maintenance treatment.

Researchers found:

Longer overall survival — People receiving the combination lived a median of 21.1 months, compared with 12.7 months for those receiving durvalumab alone.
More time before cancer worsened — Median progression-free survival — the time people lived without their cancer worsening — was 7.4 months with the combination, compared with 1.9 months with durvalumab alone. This measure also accounts for deaths.
Higher survival rates after one year — Nearly 80 percent of people receiving the combination were alive one year after starting maintenance treatment, compared with 53 percent of those receiving durvalumab alone.

These results suggest that the combination may help some people with extensive-stage SCLC live longer without their cancer worsening.

Why Do These Findings Matter for People With SCLC?

For people living with extensive-stage SCLC, these findings offer hope for a treatment approach that may help extend survival and delay cancer progression.

However, the results don’t mean that the combination is appropriate for everyone. Although tarlatamab is already FDA-approved for certain people with extensive-stage SCLC, its use alongside durvalumab as first-line maintenance treatment remains investigational.

If you’re living with extensive-stage SCLC, consider asking your oncology team what maintenance treatments are currently available, whether these findings may apply to you, and whether participating in a clinical trial might be an option.

Your care team can also help you understand the potential benefits and risks of different treatments.

Share this article
All updates must be accompanied by text or a picture.

We'd love to hear from you! Please share your name and email to post and read comments.

You'll also get the latest articles directly to your inbox.

Subscriber Photo Subscriber Photo Subscriber Photo
105,384 members
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy • Terms of Use
All updates must be accompanied by text or a picture.

Subscribe now to ask your question, get answers, and stay up to date on the latest articles.

Get updates directly to your inbox.

Subscriber Photo Subscriber Photo Subscriber Photo
105,384 members
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy • Terms of Use
Continue with Facebook
Continue with Google
By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.
Already a member? Log In

Thank you for subscribing!

Become a member to get even more

See answer